ISIN | LU2207278669 |
---|---|
Valor Number | 114371863 |
Bloomberg Global ID | |
Fund Name | Kieger Impact Healthcare Fund Class R USD Accumulating |
Fund Provider |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Phone: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
Fund Provider | Kieger AG |
Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 82.23 USD | 31.07.2025 |
---|---|---|
Previous Price * | 84.42 USD | 30.07.2025 |
52 Week High * | 96.68 USD | 30.01.2025 |
52 Week Low * | 81.01 USD | 08.04.2025 |
NAV * | 82.23 USD | 31.07.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 60,265,534 | |
Unit/Share Assets *** | 1,645 | |
Trading Information SIX |
YTD Performance | -5.22% |
31.12.2024 - 31.07.2025
31.12.2024 31.07.2025 |
---|---|---|
YTD Performance (in CHF) | -15.18% |
31.12.2024 - 31.07.2025
31.12.2024 31.07.2025 |
1 month | -8.22% |
30.06.2025 - 31.07.2025
30.06.2025 31.07.2025 |
3 months | -5.08% |
30.04.2025 - 31.07.2025
30.04.2025 31.07.2025 |
6 months | -14.16% |
31.01.2025 - 31.07.2025
31.01.2025 31.07.2025 |
1 year | -12.07% |
31.07.2024 - 31.07.2025
31.07.2024 31.07.2025 |
2 years | -21.33% |
31.07.2023 - 31.07.2025
31.07.2023 31.07.2025 |
3 years | -17.77% |
06.07.2023 - 31.07.2025
06.07.2023 31.07.2025 |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Sandoz Group AG Registered Shares | 3.78% | |
---|---|---|
Novo Nordisk AS Class B | 3.70% | |
Demant AS | 3.65% | |
Axsome Therapeutics Inc | 3.63% | |
Sanofi SA | 3.62% | |
RadNet Inc | 3.61% | |
Hikma Pharmaceuticals PLC | 3.54% | |
Hypera SA | 3.49% | |
Hologic Inc | 3.49% | |
Ambu AS Class B | 3.48% | |
Last data update | 30.04.2025 |
TER *** | 2.22% |
---|---|
TER date *** | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 2.00% |
Ongoing Charges *** | 2.22% |
SRRI ***
|
|
SRRI date *** | 30.06.2025 |